Change in TNF-α receptor expression is a relevant event in doxorubicin-induced H9c2 cardiomyocyte cell death

Journal of Interferon and Cytokine Research

Volumn 27, Issue 7, 2007, Pages 589-597

  Chiosi, Emilio ^a   Spina, Annamaria ^a   Sorrentino, Annunziata ^a   Romano, Maria ^a   Sorvillo, Luca ^a   Senatore, Giovanna ^a   D'Auria, Raffaella ^a   Abbruzzese, Alberto ^a   Caraglia, Michele ^b   Naviglio, Silvio ^a   Illiano, Gennaro ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CASPASE; DOXORUBICIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CARDIOTOXICITY; CELL DEATH; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVATION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; DOXORUBICIN; HUMANS; I-KAPPA B PROTEINS; MYOCYTES, CARDIAC; OSTEOSARCOMA; RATS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547168365     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2006.0161     Document Type: Article

References (56)

1. Zucchi R, Danesi R. Cardiac toxicity of antineoplastic anthracyclines. Curr. Med. Chem. Anticancer Agents 2003;3:151-171.
2. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 1998;339:900-905.
3. Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004;30:181-191.
4. Lipshultz SE, Sallan SE. Cardiovascular abnormalities in long-term survivors of childhood malignancy. J. Clin. Oncol. 1993;11:1199-1203.
5. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-1677.
6. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999; 57:727-741.
7. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004;56:185-229.
8. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 2000;60:1789-1792.
9. Green PS, Leeuwenburgh C. Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim. Biophys. Acta 2002;1588:94-101.
10. Li K, Sung RY, Huang WZ, Yang M, Pong NH, Lee SM, Chan WY, Zhao H, To MY, Fok TF, Li CK, Wong YO, Ng PC. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 2006;113:2211-2220.
11. Lien YC, Lin SM, Nithipongvanitch R, Oberley TD, et al. Tumor necrosis factor receptor deficiency exacerbated adriamycin-induced cardiomyocytes apoptosis: an insight into the Fas connection. Mol. Cancer Ther. 2006;5:261-269.
12. Kluza J, Marchetti P, Gallego MA, Lancel S, Fournier C, Loyens A, Beauvillain JC, Bailly C. Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 2004;23: 7018-7030.
13. Thorburn A, Frankel AE. Apoptosis and anthracycline cardiotoxicity. Mol. Cancer Then 2006;5:197-199.
14. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 2002;91:988-998.
15. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, McTiernan C. The role of tumor necrosis factor in the pathophysiology of heart failure. J. Am. Coll. Cardiol. 2000;35:537-544.
16. Sack MN, Smith RM, Opie LH. Tumor necrosis factor in myocardial hypertrophy and ischaemia - an anti apoptotic perspective. Cardiovasc. Res. 2000;45:688-695.
17. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 2003;14: 185-191.
18. Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 2003;14:193-209.
19. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003;22:8543-8567.
20. Kimes BW, Brandt BL. Properties of a clonal muscle cell line from rat heart. Exp. Cell Res. 1976;98:367-381.
21. Bergmann MW, Loser P, Dietz R, von Harsdorf R. Effect of NF-kappa B Inhibition on TNF-alpha-induced apoptosis and downstream pathways in cardiomyocytes. J. Mol. Cell Cardiol. 2001;33:1223-1232.
22. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, Malan D, Baj G, Granata R, Broglio F, Papotti M, Surico N, Bussolino F, Isgaard J, Deghenghi R, Sinigaglia F, Prat M, Muccioli G, Ghigo E, Graziani A. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J. Cell Biol. 2002;159:1029-1037.
23. Illiano G, Naviglio S, Pagano M, Spina A, Chiosi E, Barbieri M, Paolisso G. Leptin affects adenylate cyclase activity in H9c2 cardiac cell line: effects of short- and long-term exposure. Am. J. Hypertens. 2002;15:638-643.
24. Pagano M, Naviglio S, Spina A, Chiosi E, Castoria G, Romano M, Sorrentino A, Illiano F, Illiano G. Differentiation of H9c2 cardiomyoblasts: the role of adenylate cyclase system. J. Cell. Physiol. 2004;198:408-416.
25. L'Ecuyer T, Allebban Z, Thomas R, Vander Heide R. Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death. Am. J. Physiol. Heart Circ. Physiol. 2004;286:H2057-2064.
26. L'Ecuyer T, Sanjeev S, Thomas R, Novak R, Das L, Campbell W, Vander Heide RS. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am. J. Physiol. Heart Circ. Physiol. 2006;291:H1273-1280.
27. Spallarossa P, Altieri P, Garibaldi S, Ghigliotti G, Barisione C, Manca V, Fabbi P, Ballestrero A, Brunelli C, Barsotti A. Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: the role of MAP kinases and NAD(P)H oxidase. Cardiovasc. Res. 2006;69:736-745.
28. Li W, Lam MS, Birkeland A, Riffel A, Montana L, Sullivan ME, Post JM. Cell-based assays for profiling activity and safety properties of cancer drugs. J. Pharmacol. Toxicol. Methods 2006;54:313-319.
29. Liou ML, Liou HC. The ubiquitin-homology protein, DAP-1, associates with tumor necrosis factor receptor (p60) death domain and induces apoptosis. J. Biol. Chem. 1999;274:10145-10153.
30. Wu WS, Xu ZX, Hittelman WN, Salomoni P, Pandolfi PP, Chang KS. Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-kappaB survival pathway. J. Biol. Chem. 2003;278:12294-12304.
31. Wallach-Dayan SB, Izbicki G, Cohen PY, Gerstl-Golan R, Fine A, Breuer R. Bleomycin initiates apoptosis of lung epithelial cells by ROS but not by Fas/FasL pathway. Am. J. Physiol. Lung Cell Mol. Physiol. 2006;290:L790-796.
32. Albihn A, Loven J, Ohlsson J, Osorio LM, Henriksson M. c-Myc-dependent etoposide-induced apoptosis involves activation of Bax and caspases, and PKCdelta signaling. J. Cell. Biochem. 2006;98:1597-1614.
33. Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell. Biol. 1999;19:5923-5929.
34. Lou H, Danelisen I, Singal PK. Cytokines are not upregulated in adriamycin-induced cardiomyopathy and heart failure. J. Mol. Cell. Cardiol. 2004;36:683-690.
35. Hoda EM, Asker ME, Ali SI, Abd El Fattah TM. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4. J. Pharm. Pharmacol. 2004;56:757-768.
36. Safrit JT, Bonavida B. Sensitivity of resistant human tumor cell lines to tumor necrosis factor and adriamycin used in combination: correlation between down-regulation of tumor necrosis factor-messenger RNA induction and overcoming resistance. Cancer Res. 1992;52:6630-6637.
37. Watanabe N, Okamoto T, Tsuji N, Sasaki H, Akiyama S, Kobayashi D, Sato T, Yamauchi N, Niitsu Y. Reversal of tumor necrosis factor resistance in tumor cells by adriamycin via suppression of intracellular resistance factors. Jpn. J. Cancer Res. 1995;86:395-399.
38. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 1990;323:236-421.
39. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br. Heart J. 1994;72:561-566.
40. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J. Cardiac Fail. 1996; 2:243-249.
41. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. 1996;27: 1201-1206.
42. Torre-Amione G, Vooletich MT, Farmer JA. Role of tumour necrosis factor-alpha in the progression of heart failure: therapeutic implications. Drugs 2000;59:745-751.
43. Sullivan G, Carper HT, Mandel GL. The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-α-primed neutrophil oxidative activity. Int. J. Immunopharmacol. 1999;17:793-803.
44. Harada N, Okajima K, Murakami K, Usune S, Sato C, Ohshima K, Katsuragi T. Adenosine and selective A(2A) receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation. J. Pharmacol. Exp. Ther. 2000;294:1034-1042.
45. Yi X, Bekeredjian R, Defilippis NJ, Siddiquee Z, Fernandez E, Shohet RV. Transcriptional analysis of doxorubicin-induced cardiotoxicity. Am. J. Physiol. Heart Circ. Physiol. 2006;290: H1098-1102.
46. Lien YC, Daosukho C, Clair DKS. TNF receptor deficiency reveals a translational control mechanism for adriamycin-induced Fas expression in cardiac tissues. Cytokine 2006;33:226-230.
47. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, Glembotski CC, Quintana PJ, Sabbadini RA. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J. Clin. Invest. 1996;98:2854-2865.
48. Caraglia M, Marra M, Pelaia G, Maselli R, Caputi M, Marsico SA, Abbruzzese A. Alpha-interferon and its effects on signal transduction pathways. J. Cell. Physiol. 2005;202:323-335.
49. 125I-transferrin and enhances the in vitro targeting of human tumour cells with anti-(growth factor receptor) mAb. Cancer Immunol. Immunother. 1993;37:150-156.
50. Caraglia M, Pinto A, Correale P, Zagonel V, Genua G, Leardi A, Pepe S, Bianco AR, Tagliaferri P. 5-Aza-2′-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells. Ann. Oncol. 1994;5:269-276.
51. Caraglia M, Tagliaferri P, Marra M, Giuberti G, Budillon A, Di Gennaro E, Pepe S, Vitale G, Improta S, Tassone PF, Venuta S, Bianco AR, Abbruzzese A. EGF activates an inducible survival response via the RAS → ERK-1/2 pathway to counteract interferon-α-mediated apoptosis in epidermoid cancer cells. Cell Death Differ. 2003;10:218-229.
52. Cao W, Ma SL, Tang J, Shi J, Lu Y. A combined treatment TNF-alpha/doxorubicin alleviates the resistance of MCF-7/Adr cells to cytotoxic treatment. Biochem. Biophys. Acta 2006;1763:182-187.
53. Sacchi A, Gasparri A, Gallo-Stampino C, Toma S, Curnis F, Corti A. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha. Clin. Cancer Res. 2006;12:175-182.
54. Mirandola P, Sponzilli I, Gobbi G, Marmiroli S, Rinaldi L, Binazzi R, Piccari GG, Ramazzotti G, Gaboardi GC, Cocco L, Vitale M. Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins. Int. J. Oncol. 2006;28:127-133.
55. Feldman AM, McTiernan C. Is there any future for tumor necrosis factor antagonists in chronic heart failure? Am. J. Cardiovasc. Drugs 2004;4:11-19.
56. Brown SJ, Abreu MT. Antibodies to tumor necrosis factor-alpha in the treatment of Crohn's disease. Curr. Opin. Drug Discov. Dev. 2005;8:160-168.